Identification of treatment effect modifiers and prognostic factors in newly diagnosed and relapsed or refractory multiple myeloma
Journal of Comparative Effectiveness Research · 2025-10 · 14 (10)
DOI: 10.57264/cer-2024-0180 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2025-10. Verfasst von Jianming He und 9 weiteren Autor:innen. Beteiligte Einrichtung: Johnson and Johnson, Raritan, NJ 08869, USA. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
We aimed to identify variables that affect the prognosis and treatment effect in multiple myeloma (MM). Materials & methods: Published literature of randomized controlled trials (RCTs) and population-adjusted indirect comparisons (PAICs) in newly diagnosed (ND) and relapsed/refractory (RR) MM populations reporting overall survival (OS) and progression-free survival (PFS) were identified. Possible treatment effect modifiers (TEMs) were evaluated based on the ratio between effect estimates of different strata within subgroups for OS and PFS among eligible RCTs. Potential prognostic factors (PFs) were identified using the lists of covariates adjusted for in PAICs meeting the eligibility criteria.
Results
Sixty-five RCTs and 59 PAICs were included for synthesis. In ND-MM and RR-MM patients, age, sex, International Staging System stage, and cytogenetics were identified as potential TEMs for PFS based on data from published RCTs. Refractory disease, prior therapy exposure status and creatinine clearance were additional TEMs for PFS in RR-MM patients. Eastern Cooperative Oncology Group performance score and creatinine clearance were TEM candidates of PFS for ND-MM stem-cell transplant-ineligible patients. No consistent TEMs for OS were identified across all MM populations. Commonly adjusted variables for both OS and PFS in published PAICs of all populations aligned with potential TEMs of PFS identified in published RCTs. Additionally, subtype of MM, time since diagnosis and extramedullary disease or presence of plasmacytoma were common variables for adjustment in PAICs evaluating RR-MM. Frequency of each variable adjusted for differs by population and outcome. Only one PAIC reported TEMs separately from PFs.
Conclusion
TEMs and PFs identified herein can help inform future clinical trial design and serve as a primer when conducting PAICs evaluating OS and PFS in ND/RR-MM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Johnson and Johnson, Raritan, NJ 08869, USA.
- EVERSANA™, ON L7N 3H8, Canada.
- Clinical Pharmacology and Pharmacometrics, Johnson and Johnson, Breda, Netherlands.
- Johnson and Johnson, Beerse, Belgium.
ORCID-Profile: Jianming He, Karen Chiang, John Maringwa, Lingfeng Yang, Mi Jun Keng, Imtiaz A Samjoo
Zitieren
APA
He, J., Chiang, K., Lin, X., Kwong, W. J., Maringwa, J., Yang, L., Nair, S., Hashim, M., Keng, M. J., & Samjoo, I. A. (2025). Identification of treatment effect modifiers and prognostic factors in newly diagnosed and relapsed or refractory multiple myeloma. Journal of Comparative Effectiveness Research, 14(10). https://doi.org/10.57264/cer-2024-0180
Vancouver
He J, Chiang K, Lin X, Kwong WJ, Maringwa J, Yang L, et al. Identification of treatment effect modifiers and prognostic factors in newly diagnosed and relapsed or refractory multiple myeloma. Journal of Comparative Effectiveness Research. 2025;14(10). doi:10.57264/cer-2024-0180
BibTeX
@article{He2025,
author = {He, Jianming and Chiang, Karen and Lin, Xiwu and Kwong, Winghan Jacqueline and Maringwa, John and Yang, Lingfeng and Nair, Sandhya and Hashim, Mahmoud and Keng, Mi Jun and Samjoo, Imtiaz A},
title = {Identification of treatment effect modifiers and prognostic factors in newly diagnosed and relapsed or refractory multiple myeloma},
journal = {Journal of Comparative Effectiveness Research},
year = {2025},
volume = {14},
number = {10},
doi = {10.57264/cer-2024-0180}
}
EUVIMED